174 related articles for article (PubMed ID: 31119966)
1. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.
Foss FM; Parker TL; Girardi M; Li A
Leuk Lymphoma; 2019 Dec; 60(12):2927-2930. PubMed ID: 31119966
[TBL] [Abstract][Full Text] [Related]
2. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.
Koch E; Story SK; Geskin LJ
Leuk Lymphoma; 2013 Nov; 54(11):2448-51. PubMed ID: 23442065
[TBL] [Abstract][Full Text] [Related]
3. Pralatrexate (Folotyn).
Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
[TBL] [Abstract][Full Text] [Related]
4. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Jennifer C Z; Sara Mohamed J; Salma A; Francine F
Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
[TBL] [Abstract][Full Text] [Related]
5. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Horwitz SM; Kim YH; Foss F; Zain JM; Myskowski PL; Lechowicz MJ; Fisher DC; Shustov AR; Bartlett NL; Delioukina ML; Koutsoukos T; Saunders ME; O'Connor OA; Duvic M
Blood; 2012 May; 119(18):4115-22. PubMed ID: 22394596
[TBL] [Abstract][Full Text] [Related]
6. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
Duvic M; Kim YH; Zinzani PL; Horwitz SM
Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
[No Abstract] [Full Text] [Related]
7. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
Hong JY; Yoon DH; Yoon SE; Kim SJ; Lee HS; Eom HS; Lee HW; Shin DY; Koh Y; Yoon SS; Jo JC; Kim JS; Kim SJ; Cho SH; Lee WS; Won JH; Kim WS; Suh C
Sci Rep; 2019 Dec; 9(1):20302. PubMed ID: 31889144
[TBL] [Abstract][Full Text] [Related]
8. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.
Foss FM; Parker TL; Girardi M; Li A
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e445-e447. PubMed ID: 30181105
[No Abstract] [Full Text] [Related]
9. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
[TBL] [Abstract][Full Text] [Related]
10. Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind.
Altınay S; Kural A; Özmen A; Tural D; Tutar Y
Anticancer Agents Med Chem; 2023; 23(3):298-305. PubMed ID: 35692151
[TBL] [Abstract][Full Text] [Related]
11. Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
Lee SS; Jung SH; Ahn JS; Kim YK; Cho MS; Jung SY; Lee JJ; Kim HJ; Yang DH
J Korean Med Sci; 2016 Jul; 31(7):1160-3. PubMed ID: 27366017
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
[TBL] [Abstract][Full Text] [Related]
13. Pralatrexate experience in PTCL: A multicenter retrospective study from Turkey.
Sinan Dal M; Merdin A; Erkurt MA; Ekinci Ö; Albayrak M; Kabukcu Hacıoglu S; Kaya A; Dogu MH; Hindilerden F; Sarici A; Merter M; Reis Aras M; Akgun Caglıyan G; Kizil Cakar M; Aydogdu I; Kuku I; Korkmaz S; Ulas T; Eser B; Altuntas F
J BUON; 2021; 26(4):1536-1539. PubMed ID: 34565016
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
Maruyama D; Nagai H; Maeda Y; Nakane T; Shimoyama T; Nakazato T; Sakai R; Ishikawa T; Izutsu K; Ueda R; Tobinai K
Cancer Sci; 2017 Oct; 108(10):2061-2068. PubMed ID: 28771889
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
Foss FM
Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
[TBL] [Abstract][Full Text] [Related]
17. [Leucovorin Administration Allows Continued Pralatrexate Treatment in a Patient with Angioimmunoblastic T-Cell Lymphoma].
Sawada K; Sata H; Yasumi M; Karasuno T
Gan To Kagaku Ryoho; 2020 Jan; 47(1):95-97. PubMed ID: 32381871
[TBL] [Abstract][Full Text] [Related]
18. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
19. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
[TBL] [Abstract][Full Text] [Related]
20. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
